March 5, 2023 — The number of deaths and disabling strokes among patients at low surgical risk who were treated with transcatheter aortic valve replacement (TAVR) remained lower at three years, but not significantly lower, following the TAVR procedure compared with patients who received conventional
March 5, 2023 — Patients with complex coronary artery disease who underwent a stenting procedure guided by intravascular imaging were nearly 40% less likely to die of heart disease, have a heart attack caused by a new blockage in the treated artery or need a repeat stenti
March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology’s Annual Scientific Session Together With the
March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure using a clip to repair the valve was safe, cut the rate of hospitalizations for heart failure by 47% and reduced deaths from any cause by almost 30% after five years of follow-up, according to a study presented at the American College of Cardiology’s Ann
March 5, 2023 — In the largest randomized trial conducted to compare minimally invasive and conventional cardiac surgical techniques for repairing a poorly functioning mitral valve, improvements in physical activity, as well as surgical outcomes and quality of life, were similar in both groups of patients at 12 weeks post-surgery.
March 4, 2023 — The impact of statin use to prevent heart damage during a cancer patient’s chemotherapy was in focus during a late-breaking scientific session, on the STOP-CA Trial, presented at the American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC, being held March 4-6 in
March 4, 2023 - Lexicon Pharmaceuticals, Inc.  announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Ann